Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Br J Dermatol. 2020 Mar 04;:
Authors: Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G
Abstract
CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis.
PMID: 32133618 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G Tags: Br J Dermatol Source Type: research
More News: Arthritis | Crohn's Disease | Dermatology | Inflammatory Bowel Disease | Men | Psoriasis | Psoriatic Arthritis | Remicade | Rheumatoid Arthritis | Rheumatology | Skin | UK Health | Ulcerative Colitis